for more on takeda's earnings, i am joined by christophe weber, takeda pharmaceuticals president andu for joining me. i don't see how you are not come to have some kind of impact from covid, considering a large part of your business comes from the u.s. how do you see the virus playing out? know, our: you portfolio of medicine's life-saving medicines, so we are treating very severe disease, and you cannot stop the treatment for the disease for really lifesaving medicines. they are not linked to elective surgery. i think there will be some impact in some products, but overall, we feel confident that over time, our medicine will still be used by patients. alix: but unless i'm wrong, it seems like one of your main drugs is for crohn's disease, which isn't necessarily life-threatening, and your other is for a plasma business, and that basically means an infusion. i have a hard time to gain that is still going to be safe, or people are going to be ok doing that in the short-term. christophe: you know, would you have crohn's disease, you want to continue to get your treatment. it is not lif

vonnie: for more insight, we are joined by takeda's rajeev venkayya.ust comment if you would, president trump's comments we would have a vaccine by the end of the year. takeda is looking also to get , but fromaccine area your perspective is it a possibility we would have a workable one by the end of the year? it is possible but it is going to be extraordinarily ambitious. christie is right, it typically takes many years -- president trump is right, it typically takes many years, 10, 15 or longer. is in and ofhat itself extraordinary. target of having meaningful quantities by the end of the calendar year is extremely ambitious. i don't think anybody can guarantee this will happen. what i can say is that the industry is doing its very best as well as the regulatory authorities to make that happen. tonie: takeda is looking develop some kind of vaccine perhaps in partnership with others. you have a plasma business you're going to direct towards covid-19 treatments. explain why you would do that given that there are so many efforts for vaccines out there an

romaine: we were speaking to the head of global business at takeda pharmaceuticals speaking a littlearlier. the airline industry has been one of the sectors hit hardest. the latest knock was that news that berkshire hathaway had sold off its main stake in four of the main carriers in the u.s. justin bachman covers airlines for bloomberg news. an idea that you remove investor like profit out of this industry, you remove a level of support that people thought would be there for a while and could be the potential saving grace of this industry. is the industry on enough solid footing? moment, thehe answer is yes. they have lined up as of dollars in liquidity from the government and private sources. they will get just fine in the next few months. i think the question becomes, how long does this revenue downturn last? a lot of analysts are worried about, if this is the current state at the end of the year, then things start to change. then you see some airlines get into financial trouble as far as their cash position. when passenger traffic returns is really the trillion dollar question fo

takeda is one of the biggest makers of plasma therapies they say their plasma therapy for covid-19 istart trials in summer with the first patient to be enrolled in july this is a similar approach to the convalescent plasma approach where somebody donates their plasma this is a turbo charge to that takeda is doing that in alliance with a number of other plasma companies around the world in a very unique kind of approach guys joe, back to you >> let's bring in the cfo of takeda pharmaceutical, christopher weber. thanks for joining us this morning. give us a best scenario timeline for some type of plasma treatment for covid-19 patients, in your view >> good morning, joe and good morning everyone thank you for giving me an opportunity. so we initiated this treatment approach a few weeks ago in fact, quite rapidly we understood we could do a better job by creatingan alliance wit other companies in the field so right now what we have been doing is collecting plasma from a patient who had recovered from covid-19, from the coronavirus we have enough to actually start manufacturing of the clin

haidi: to keita says it plans -- takeda plans a plasma based therapy as soon as july. is optimistic about the company's future. he spoke to bloomberg. >> a life-saving medicine. we are treating a very severe disease. treatment stop the for the disease. they are not linked to elective surgery. i think there will be some impact in some product, but overall we feel confident that, over time, our medicine will still be used by patients. >> unless i'm wrong, it seems like one of your main drugs is for crohn's disease, which is not life-threatening, and the other is for a plasma business. i have a hard time thinking that is still going to be safe or people will be ok doing that in the short term. >> when you have hundreds disease, you want -- crohn's disease, you want to continue to take your treatment. iscourse getting an infusion more complicated, but time is needed to get your treatment. there will be short-term impact. confident about the guidance we gave today. when it comes to the global treatment, you are trading primary immunodeficiency, which could be life-threateni

. -- takeda. more green on the screen this tuesday morning. we have china and south korea and japan closed for holidays. limited trading but we are seeing a better picture from yesterday. jakarta just coming online. up 241. seng retail sales look ugly as well. 48% afterof a drop of we saw the worst quarter on record for gdp in the first quarter. nifty futures pointing positive. - -nfte. it was not telling much when it comes to the futures market and when markets opened in mumbai after the drop in nifty and the sensex yesterday. we are watching the rmb but we 56.off the lows around 711. the u.s. wrapping up pressure on beijing and it will be interesting what happens tomorrow, when the pboc reopens trade -- markets reopen trade and that pbo css the daily effects. take a look at currency. it has been a mixed bag and we are watching the aussie dollar with the bank meeting today. bank negara could be interesting expecting a 50 basis point cut later today. are watching dollar-yen summit strength low 107 now. take a look at your commodities markets,

japan's takeda says president trump's plan that one will be ready by year-end is extremely ambitious, the president of the global vaccine business is not ruling out the possibility. but it isossible, going to be extraordinarily ambitious and challenging. president trump is right that it typically takes many, many years to produce a vaccine. i would say that for many vaccines, it taken 10 to 15 years or longer, so to compress that to the stated 12 months to and of itself in extraordinary, but to set a target to having meaningful quantities of vaccine by the end of this calendar year is really, really, extremely ambitious. i don't think anybody can guarantee that this will happen, but what i can say is that the industry is doing its very best as well as the regulatory authorities and the scientific community, to make that happen. toi know takeda is looking try to develop some kind of vaccine, may be in partnership with others as well. you have a plasma business that you are going to direct towards covid-19 treatment. so explain to us why you would do that given that there's so many diff